FK506 increased endothelial cPKCβII activation, which was prevented by the cPKCβII isoform-specific peptide inhibitor. FK506 treatment significantly increased phosphorylation of cPKCβII at Thr641, and this was prevented by the cPKCβII isoform-specific peptide inhibitor. Top, representative immunoblots. Con, control. Bottom, densitometry for the percentage change in the ratio of pPKC Thr641 to actin. *, p < 0.05. n = 4 independent experiments.